c340b651-bd01-4194-a67b-e801d0feeb2b
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.490
- MTORC1_SIGNALING+0.490
- TNFA_SIGNALING_VIA_NFKB+0.490
- OXIDATIVE_PHOSPHORYLATION+0.470
- INTERFERON_GAMMA_RESPONSE+0.440
- MYC_TARGETS_V1+0.430
- CHOLESTEROL_HOMEOSTASIS+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.400
- PI3K_AKT_MTOR_SIGNALING+0.350
- PROTEIN_SECRETION+0.340
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- MYOGENESIS-0.340
- ANGIOGENESIS-0.300
- HEDGEHOG_SIGNALING-0.290
- WNT_BETA_CATENIN_SIGNALING-0.260
- COAGULATION-0.220
- APICAL_JUNCTION-0.190
- KRAS_SIGNALING_DN-0.190
- UV_RESPONSE_DN-0.060
- MITOTIC_SPINDLE-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013490 | — | cohortA4 | 0.884 |
| 2 | SRR5903550 | — | cohortA4 | 0.865 |
| 3 | SRR10899985 | — | — | 0.861 |
| 4 | MNG533 | — | — | 0.859 |
| 5 | SRR12696807 | — | — | 0.859 |
| 6 | TCGA-AO-A0J2-01A-11R-A034-07 | — | C | 0.854 |
| 7 | SRR35579824 | — | E | 0.854 |
| 8 | bf312cd5-e251-4d63-95b5-c379b3ef5ded | — | — | 0.850 |
| 9 | SRR1313147 | — | E | 0.848 |
| 10 | ddd65fce-1a39-415c-9114-7a9c8e9b266c | — | — | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.490 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.410 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.290 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |